Tegafur/gimeracil/oteracil (Teysuno®)

All Wales Medicines Strategy Group (AWMSG)
Record ID 32013001027
Authors' recommendations: Tegafur/gimeracil/oteracil (Teysuno®) is recommended as an option for restricted use within NHS Wales in adults for the treatment of advanced gastric cancer when given in combination with cisplatin, when standard triplet therapy is not suitable.
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Wales, United Kingdom
MeSH Terms
  • Humans
  • Stomach Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
  • Antimetabolites, Antineoplastic
  • Tegafur
  • Pyridines
  • Oxonic Acid
Organisation Name: All Wales Medicines Strategy Group
Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name: AWTTC@wales.nhs.uk
Contact Email: AWTTC@wales.nhs.uk
Copyright: AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.